scanX
Alembic Pharmaceuticals
add_icon

Alembic Pharmaceuticals

723.55
-1.95
(-0.27%)
Market Cap
14,222.32 Cr
PE Ratio
21.21
Volume
68,595.00
Day High - Low
728.00 - 710.60
52W High-Low
1,107.90 - 635.80
ann
There are 1 new updates from the company21 hrs ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
14,222.32 Cr
EPS
34.33
PE Ratio
21.21
PB Ratio
2.51
Book Value
288.70
EBITDA
1,051.47
Dividend Yield
1.66 %
Industry
Healthcare
Sector
Pharmaceuticals
Return on Equity
11.22
Debt to Equity
0.18
Analyst Rating and Forecast
- By Refinitiv from9 analysts
HOLD
Analysts have suggested that investors can hold this stock
Buy
Buy+44.44 %
+44.44 %
Hold
Hold+55.56 %
+55.56 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Alembic Pharma designates Ramesh Juneja as Senior Management1 day ago
Alembic Pharmaceuticals designated Mr. Ramesh Juneja as Senior Management Personnel effective June 1, 2026. He brings over three decades of experience in pharmaceutical sales and marketing.
neutral
Alembic to attend Trinity India 20269 days ago
Alembic Pharmaceuticals will participate in the Trinity India 2026 conference in Mumbai on May 29, 2026, meeting institutional investors.
positive
Alembic Pharma Gets USFDA Final Nod for LevothyroxineMay 22, 2026
Alembic Pharmaceuticals secures USFDA final approval for Levothyroxine Sodium Tablets, targeting a projected market size of $1.87 billion by March 2026.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,788.50
#1 4,29,121.06
37.31
#1 58,220.10
6.38
#1 11,565
25.80
44.37
Divis Laboratories
6,576.50
1,74,585.41
67.49
10,560.00
8.73
2,520
13.44
46.75
Torrent Pharmaceuticals
4,368.50
1,47,849.89
68.30
13,753.00
19.18
2,028
-26.91
50.11
Cipla
1,375.20
1,11,086.00
28.84
27,711.70
-2.46
3,783
-55.32
52.65
Zydus Life Science
1,076.60
1,08,331.15
21.16
26,719.70
13.65
5,242
7.82
68.91
Dr Reddys Laboratories
1,263.30
1,05,440.45
25.59
33,593.30
-0.44
3,998
-86.05
41.47
Lupin
2,261.20
1,03,346.61
#1 19.21
27,487.50
19.98
5,345
#1 87.72
45.17
Mankind Pharma
2,369.50
97,814.16
48.97
14,277.60
12.03
1,750
31.75
50.42
Aurobindo Pharma
1,440.40
83,658.67
23.70
33,384.70
3.21
3,376
1.99
48.90
Laurus Labs
1,394.30
75,272.20
83.88
6,812.90
#1 21.03
884
21.18
76.00

Automatic Screeners on ScanX

Community
Day 1 Unusual Volume
Community
Support 1 Breached
Growth Rate
Revenue Growth
9.39 %
Net Income Growth
-2.69 %
Cash Flow Change
-89.05 %
ROE
-12.21 %
ROCE
6.31 %
EBITDA Margin (Avg.)
-9.20 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Revenue
504
582
1,003
918
630
737
880
777
742
648
797
840
854
863
1,129
1,022
930
952
1,241
1,210
1,243
1,342
1,460
1,317
1,306
1,328
1,313
1,291
1,426
1,263
1,475
1,510
1,407
1,498
1,605
1,634
1,521
1,564
1,678
1,703
1,784
1,717
1,919
1,892
1,874
Expenses
405
478
629
532
484
580
702
632
606
547
610
653
680
712
825
776
749
757
895
884
926
934
1,014
949
960
1,090
1,054
1,030
1,268
1,255
1,244
1,274
1,203
1,288
1,387
1,364
1,257
1,325
1,409
1,433
1,498
1,430
1,595
1,627
1,645
EBITDA
99
103
375
386
146
158
178
146
136
102
187
188
174
151
305
246
181
195
346
326
318
408
447
368
346
238
259
261
158
9
231
236
205
210
218
269
263
239
270
270
286
287
324
265
230
Operating Profit %
19 %
18 %
37 %
42 %
23 %
21 %
20 %
19 %
18 %
16 %
23 %
22 %
20 %
18 %
27 %
24 %
19 %
20 %
28 %
27 %
23 %
30 %
30 %
28 %
25 %
18 %
18 %
19 %
10 %
1 %
16 %
16 %
14 %
13 %
13 %
16 %
17 %
15 %
15 %
15 %
15 %
16 %
17 %
13 %
11 %
Depreciation
11
13
13
22
24
19
21
21
22
22
26
26
32
28
29
29
30
35
36
42
44
42
44
47
51
53
55
56
123
67
68
67
74
66
68
69
70
69
71
70
69
74
76
80
89
Interest
0
1
1
1
2
1
1
1
2
1
0
1
1
2
6
6
5
5
7
7
8
7
5
2
3
2
5
4
7
9
12
15
14
14
16
15
11
13
19
22
25
24
24
23
23
Profit Before Tax
89
91
362
364
120
137
157
124
112
79
161
161
141
122
270
211
146
155
303
276
266
360
398
318
292
183
200
201
29
-67
151
155
116
130
135
185
183
157
180
178
192
190
224
162
119
Tax
18
19
73
95
29
33
37
37
19
12
39
30
47
32
70
42
23
36
52
49
62
66
73
33
49
24
36
29
7
-2
18
33
-36
9
-2
4
5
23
27
40
35
37
40
30
-83
Net Profit
70
72
289
269
91
104
120
87
93
67
122
131
94
90
200
169
124
120
250
227
204
293
325
286
243
158
164
172
22
-66
133
122
153
121
137
180
178
135
153
138
157
154
184
132
202
EPS in ₹
3.73
3.72
15.30
14.26
4.82
5.50
6.36
4.59
4.94
3.54
6.45
6.93
4.98
4.80
10.61
9.01
6.58
6.56
13.06
12.42
11.93
15.99
17.24
14.88
12.75
8.37
8.34
8.74
1.11
-3.35
6.78
6.20
7.76
6.14
6.95
9.23
9.07
6.84
7.79
7.01
7.98
7.85
9.40
6.76
10.31
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total Assets
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
8,763
Fixed Assets
547
708
799
993
1,159
1,552
1,788
1,798
2,398
2,547
2,524
3,764
Current Assets
891
1,511
1,373
1,825
1,958
2,463
2,652
2,861
2,910
3,079
4,088
4,573
Capital Work in Progress
83
93
396
1,010
1,551
1,846
2,183
2,304
601
524
837
634
Investments
0
53
50
42
49
18
236
118
96
93
127
2,511
Other Assets
1,011
1,575
1,444
1,896
2,019
2,573
2,502
2,902
3,087
3,282
4,285
0
Total Equity & Liabilities
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
8,763
Current Liabilities
684
747
693
1,144
1,490
1,752
1,281
1,717
1,637
1,455
2,412
2,594
Non Current Liabilities
72
84
94
576
570
1,047
361
168
175
172
171
500
Total Equity
885
1,597
1,902
2,220
2,718
3,190
5,067
5,238
4,371
4,818
5,190
5,675
Reserve & Surplus
847
1,560
1,865
2,182
2,681
3,182
5,028
5,198
4,331
4,779
5,152
5,636
Share Capital
38
38
38
38
38
38
39
39
39
39
39
39
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
3
417
-286
-69
115
-127
26
-37
14
45
-37
Investing Activities
-256
-307
-486
-884
-756
-731
-840
-372
-448
-321
-568
Operating Activities
172
948
329
312
812
449
1,463
552
724
803
88
Financing Activities
87
-224
-129
503
59
155
-597
-217
-262
-438
444
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Promoter
69.48 %
69.48 %
69.48 %
69.48 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.67 %
69.67 %
69.74 %
69.74 %
69.74 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
4.52 %
4.46 %
4.32 %
3.94 %
4.17 %
3.94 %
3.96 %
4.05 %
4.24 %
4.25 %
DIIs
10.92 %
11.17 %
11.36 %
11.56 %
11.69 %
12.06 %
12.43 %
12.76 %
13.31 %
13.40 %
13.93 %
14.50 %
15.38 %
15.47 %
16.05 %
16.06 %
16.43 %
16.46 %
16.30 %
16.17 %
16.18 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
10.99 %
10.78 %
11.43 %
9.57 %
9.22 %
8.91 %
9.12 %
9.21 %
9.08 %
8.98 %
8.24 %
8.00 %
7.41 %
7.48 %
7.36 %
7.26 %
7.07 %
7.01 %
6.93 %
6.87 %
6.86 %
Others
8.61 %
8.57 %
7.73 %
9.39 %
9.47 %
9.41 %
8.84 %
8.42 %
8.00 %
8.01 %
8.22 %
3.37 %
3.14 %
3.13 %
3.04 %
2.90 %
2.88 %
2.89 %
2.99 %
2.98 %
2.96 %
No of Share Holders
0
0
99,809
1,01,686
1,23,059
1,10,038
1,06,437
1,01,457
1,03,811
97,607
89,552
85,212
76,567
74,829
91,429
93,944
91,336
89,013
89,969
87,000
86,432

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 4 4 5.5 10 14 10 8 11 11 0.00
Dividend Yield (%) 0.73 0.74 1.03 1.04 1.89 2.13 0.81 1.18 1.66 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
21 Jul 2021 DIVIDEND Dividend
₹ 14.00 /share
 19 Jul 2021 983.60 939.65
18 Aug 2022 DIVIDEND Dividend
₹ 10.00 /share
 17 Aug 2022 781.50 656.10
28 Jul 2023 DIVIDEND Dividend
₹ 8.00 /share
 28 Jul 2023 560.55 732.15
15 Jul 2024 DIVIDEND Dividend
₹ 11.00 /share
 15 Jul 2024 1,001.85 984.60
22 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 22 Jul 2024 845.20 1,079.55
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Nov 2024 1,182.75 1,139.20
03 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 03 Feb 2025 1,029.95 937.10
06 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 May 2025 849.90 905.45
29 Jul 2025 DIVIDEND Dividend
₹ 11.00 /share
 29 Jul 2025 905.45 1,000.40
05 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 05 Aug 2025 982.70 967.25
05 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Aug 2025 1,031.40 967.25
04 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 04 Nov 2025 932.80 924.20
05 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Feb 2026 769.80 798.35
15 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 15 May 2026 751.10 785.70

Announcements

Announcement under Regulation 30 (LODR)-Change in Management21 hrs ago
Announcement under Regulation 30 (LODR)-Change in Management1 day ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 22, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 21, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2026
Alembic Pharmaceuticals Limited Passes ANVISA (Brazil) GMP Inspection For Its API-III Facility At Karakhadi.May 15, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationMay 15, 2026
Audited Financial Results For The Quarter And Financial Year Ended 31St March 2026May 15, 2026
Board Meeting Outcome for Outcome Of Board MeetingMay 15, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 14, 2026
Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) For Its Injectable Facility (F-III) Located At Karakhadi.May 14, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2026
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 09, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 05, 2026
Intimation Under Reg 30 Of SEBI (LODR) Regulations 2015May 04, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 04, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 01, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 29, 2026
Board Meeting Intimation for Considering Audited Financial Results For The Quarter And Financial Year Ended 31St March 2026Apr 27, 2026
Announcement under Regulation 30 (LODR)-DemiseApr 27, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 25, 2026
Intimation Under Regulation 30 Of SEBI LODR Regulations 2015 - Incorporation Of Wholly-Owned Subsidiary CompanyApr 23, 2026
Intimation Under Regulation 30 Of SEBI LODR Regulations 2015 - Incorporation Of Subsidiary CompanyApr 22, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 17, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 16, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 15, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 07, 2026
Dislcosure letter under Regulation 11(5) of The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011.Apr 06, 2026
Announcement under Regulation 30 (LODR)-Change in DirectorateApr 01, 2026
Announcement under Regulation 30 (LODR)-CessationApr 01, 2026
Announcement under Regulation 30 (LODR)-Change in DirectorateApr 01, 2026
Announcement under Regulation 30 (LODR)-Change in DirectorateApr 01, 2026
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 31, 2026
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 31, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMar 31, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 27, 2026
Closure of Trading WindowMar 27, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 20, 2026
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Incorporation Of SubsidiaryMar 09, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 06, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 04, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 02, 2026
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 27, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 24, 2026

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.02%
6
0.00%
0.00%
Groww Value Fund Direct-Growth
1.05%
0
0.00%
-0.47%
HDFC Multi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Angel One Nifty Total Market Index Fund Direct-Growth
0.02%
0
0.00%
0.00%
Axis Nifty 500 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Small Cap Fund Direct-Growth
0.40%
0
0.00%
0.00%
Bajaj Finserv Healthcare Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bajaj Finserv Multi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bajaj Finserv Small Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.30%
0
0.00%
0.02%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.02%
0
0.00%
0.00%
DSP Aggressive Hybrid Fund Direct-Growth
0.53%
0
0.00%
0.04%
DSP ELSS Tax Saver Fund Direct Plan-Growth
0.66%
0
0.00%
0.03%
DSP Equity Savings Fund Direct-Growth
0.22%
0
0.00%
0.03%
DSP Healthcare Fund Direct-Growth
3.43%
0
0.00%
0.15%
DSP Large Cap Fund Direct-Growth
0.64%
0
0.00%
0.03%
DSP Midcap Direct Plan-Growth
0.82%
0
0.00%
0.02%
DSP Multi Asset Allocation Fund Direct-Growth
0.09%
0
0.00%
0.00%
DSP Multicap Fund Direct-Growth
0.35%
0
0.00%
0.00%
DSP Nifty 500 Index Fund Direct-Growth
0.00%
0
0.00%
-0.02%
DSP Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
-0.21%
DSP Regular Savings Fund Direct-Growth
0.21%
0
0.00%
0.02%
DSP Small Cap Direct Plan-Growth
0.63%
0
0.00%
-0.02%
DSP Value Fund Direct-Growth
0.28%
0
0.00%
-0.01%

Technical Indicators

RSI(14)
Neutral
41.90
ATR(14)
Less Volatile
26.17
STOCH(9,6)
Neutral
36.18
STOCH RSI(14)
Oversold
7.37
MACD(12,26)
Bearish
-6.07
ADX(14)
Weak Trend
23.88
UO(9)
Bearish
41.90
ROC(12)
Downtrend And Accelerating
-7.66
WillR(14)
Oversold
-81.78
Bearish
4
Neutral
4
Bullish
1

About Alembic Pharmaceuticals

Alembic Pharmaceuticals is an India-based company that manufactures and markets generic pharmaceutical products globally. It operates in India Formulations, International Generics, and Active Pharmaceutical Ingredients (API) segments. The company has state-of-the-art research and manufacturing facilities approved by regulatory authorities, including the US FDA. Alembic produces a range of generics across...more
Website
https://www.alembicpharmaceuticals.com/
Chairperson NameChirayu R Amin
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

© 2025 - 2026 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104